Johnson & Johnson and Pfizer present meaningfully different leverage profiles, with Pfizer carrying substantially more gross debt relative to equity. For FY2025, JNJ's total debt sums to approximately $49.9B (long-term noncurrent $39.4B [JNJ:Q3] + current maturities $2.0B [JNJ:Q7] + short-term borrowings $8.5B [JNJ:Q11]) against stockholders' equity of $81.5B [JNJ:Q15], implying a debt-to-equity ratio of roughly 0.61x. PFE's FY2025 total debt stands at approximately $64.6B (long-term noncurrent $61.6B [PFE:Q3] + current maturities $3.0B [PFE:Q7]) against equity of $86.5B [PFE:Q15], a debt-to-equity ratio of roughly 0.75x.
On the trajectory of debt accumulation, the two companies tell distinct stories. JNJ's long-term noncurrent debt actually dipped to approximately $25.9B in FY2023 before climbing to $30.7B in FY2024 and then rising more sharply to $39.4B [JNJ:Q3] by FY2025 — meaning the bulk of the increase is concentrated in the most recent periods rather than spread evenly from FY2022's $26.9B [JNJ:Q0]. Pfizer's debt surge was more abrupt: long-term noncurrent debt nearly doubled from $32.9B [PFE:Q0] in FY2022 to $61.5B [PFE:Q1] in FY2023, driven by the debt-financed Seagen acquisition. Since then, Pfizer has shown some active debt management — noncurrent debt declined to roughly $57.4B in FY2024 before rising back to $61.6B [PFE:Q3] in FY2025 — suggesting the elevated level is not entirely static, though it remains well above pre-acquisition levels.
On a net-debt basis, the gap between the two companies widens considerably. JNJ's cash balance of $19.7B [JNJ:Q19] provides a meaningful offset to its gross debt, supporting a relatively conservative net leverage position. Pfizer, by contrast, holds only $1.1B in cash [PFE:Q19], leaving it with a substantially higher net debt burden and making debt reduction a key balance-sheet priority in the near term.
JNJ: JNJ's leverage has risen over the past few years, with FY2025 total debt of roughly $49.9B (noncurrent $39.4B [JNJ:Q3], current maturities $2.0B [JNJ:Q7], short-term borrowings $8.5B [JNJ:Q11]) against equity of $81.5B [JNJ:Q15], yielding a ~0.61x debt-to-equity ratio. The increase in long-term debt has been back-loaded, with the most notable step-up occurring in FY2024–FY2025. That said, a substantial cash position of $19.7B [JNJ:Q19] meaningfully reduces net debt, keeping the overall balance sheet relatively conservative.
PFE: Pfizer's leverage profile deteriorated sharply in FY2023 when long-term noncurrent debt nearly doubled to $61.5B [PFE:Q1] from $32.9B [PFE:Q0] in FY2022, driven by acquisition financing. The company has demonstrated some capacity for debt reduction — noncurrent debt fell to ~$57.4B in FY2024 — but it has since edged back up to $61.6B [PFE:Q3] in FY2025. With only $1.1B in cash [PFE:Q19] and equity of $86.5B [PFE:Q15], Pfizer's net debt remains substantial at a ~0.75x gross debt-to-equity ratio, and meaningful deleveraging remains a central balance-sheet challenge.
Cross-axis takeaway: Across the leverage dimension, JNJ holds a clear structural advantage — lower gross debt-to-equity, a far stronger cash cushion, and a net debt position that is manageable relative to its equity base. Pfizer's post-Seagen balance sheet carries significantly more financial risk, and while there are early signs of active debt management, the company's minimal cash reserves leave little buffer, making sustained deleveraging a prerequisite for restoring balance-sheet flexibility.